The scientific community and the impact of the Myriad Genetics Supreme Court decision
The Scientist
Most Recent
Supreme Court says no patenting (natural) genes; brain-computer interfaces mimic motor learning in brain; regenerating finger tips; gene therapy goes deeper; NIH needs more diversity; cross-border collaboration
The Supreme Court agrees to hear a case deciding if two cancer genes should continue to be protected by patent.
Myriad Genetics can hold patents on the BRAC1 and BRAC2 oncogenes, but not on tests comparing DNA sequences.
James Watson files a brief in the ongoing legal case over Myriad Genetics’ right to hold patents on the BRCA1 and BRCA2 genes.
A public interest legal group has renewed the fight against DNA patenting.
Two key patent cases that no doubt will impact the future of personalized medicine are pending review by the US Supreme Court. What will the Court decide?
The case challenging the right of a healthcare company to patent cancer genes may make it all the way to the US Supreme Court.
A US federal appeals court says human genes are patentable.
Legal battles over gene patents and uncooperative patent holders threaten the widespread implementation of personalized medicine
Page 1 of 1
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
